STAB
Income statement / Annual
Last year (2021), Statera Biopharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2021, Statera Biopharma, Inc.'s net income was -$174.41 M.
See Statera Biopharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$488,314.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit |
-$488,314.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Research and Development Expenses |
$11.83 M
|
$5.26 M
|
$587,000.00
|
$3.62 M
|
$5.05 M
|
$6.50 M
|
$7.14 M
|
$9.65 B
|
$19.53 B
|
$22.50 B
|
General & Administrative Expenses |
$18.41 M
|
$5.24 M
|
$2.23 M
|
$2.32 M
|
$2.50 M
|
$3.38 M
|
$6.36 M
|
$8.47 B
|
$12.04 B
|
$11.12 B
|
Selling & Marketing Expenses |
$79,439.00
|
$2,406.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$18.49 M
|
$5.24 M
|
$2.23 M
|
$2.32 M
|
$2.50 M
|
$3.38 M
|
$6.36 M
|
$8.47 B
|
$12.04 B
|
$11.12 B
|
Other Expenses |
-$1.49 M
|
-$461,500.00
|
-$285,613.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Operating Expenses |
$28.83 M
|
$10.50 M
|
$2.81 M
|
$5.94 M
|
$7.55 M
|
$9.87 M
|
$13.50 M
|
$18.12 B
|
$31.56 B
|
$33.62 B
|
Cost And Expenses |
$29.32 M
|
$10.50 M
|
$2.81 M
|
$5.94 M
|
$7.55 M
|
$9.87 M
|
$13.50 M
|
$18.12 B
|
$31.56 B
|
$33.62 B
|
Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
$0.00
|
$1.13 M
|
$124,233.00
|
$0.00
|
$0.00
|
$263,653.00
|
-$99,488.00
|
-$1.09 B
|
$83.13 M
|
-$70.02 M
|
Depreciation & Amortization |
$255,574.00
|
$947.00
|
$13,782.00
|
$18,175.00
|
$21,081.00
|
$63,456.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
EBITDA |
$38.93 M |
-$2.59 M |
-$2.36 M |
-$4.80 M |
-$5.60 M |
-$6.36 M |
-$10.79 M |
-$14.42 B |
-$23.08 B |
-$30.05 B |
EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Total Other Income/Expenses Net |
-$3.53 M
|
-$1.59 M
|
-$409,846.00
|
$1.19 M
|
-$4.11 M
|
$3.70 M
|
-$1.85 M
|
$16.05 B
|
$5.81 B
|
$11.81 B
|
Income Before Tax |
-$101.88 M
|
-$12.09 M
|
-$3.22 M
|
-$3.61 M
|
-$9.71 M
|
-$2.66 M
|
-$12.64 M
|
$1.63 B
|
-$17.26 B
|
-$18.23 B
|
Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Income Tax Expense |
$72.53 M
|
$1.13 M
|
$124,233.00
|
-$161,141.00
|
-$52,516.00
|
-$22,816.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Net Income |
-$174.41 M
|
-$13.22 M
|
-$3.35 M
|
-$3.61 M
|
-$9.71 M
|
-$2.66 M
|
-$12.64 M
|
$1.63 B
|
-$17.26 B
|
-$18.23 B
|
Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
EPS |
-4.97 |
-0.52 |
-0.13 |
-0.32 |
-0.87 |
-0.24 |
-1.79 |
0.6 |
-0.38 |
-0.49 |
EPS Diluted |
-4.97 |
-0.52 |
-0.13 |
-0.32 |
-0.87 |
-0.24 |
-1.79 |
0.6 |
-0.38 |
-0.49 |
Weighted Average Shares Out |
$35.11 M
|
$25.65 M
|
$25.65 M
|
$11.29 M
|
$11.19 M
|
$10.99 M
|
$7.06 M
|
$2.70 B
|
$45.00 B
|
$37.39 B
|
Weighted Average Shares Out Diluted |
$35.11 M
|
$25.65 M
|
$25.65 M
|
$11.29 M
|
$11.19 M
|
$10.99 M
|
$7.06 M
|
$2.70 B
|
$45.00 B
|
$37.39 B
|
Link |
|
|
|
|
|
|
|
|
|
|